证券日报网讯 10月24日晚间，瑞普生物发布2025年第三季度报告称，2025年第三季度公司实现营业收 入836，737，374.53元，同比增长1.44%；归属于上市公司股东的净利润为105，784，584.02元，同比 增长23.02%。 （编辑 任世碧） ...

Core Viewpoint - Reap Bio (300119.SZ) reported a strong performance in the first three quarters of 2025, with significant growth in both revenue and net profit [1] Financial Performance - The company's operating revenue for the first three quarters reached 2.544 billion yuan, representing a year-on-year increase of 13.50% [1] - The net profit attributable to shareholders of the listed company was 362 million yuan, showing a year-on-year growth of 45.64% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 269 million yuan, reflecting a year-on-year increase of 24.92% [1] - Basic earnings per share stood at 0.7972 yuan [1]

Core Insights - The company reported a revenue of 837 million yuan for Q3 2025, representing a year-on-year increase of 1.44% [1] - The net profit attributable to shareholders was 106 million yuan, showing a year-on-year growth of 23.02% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 81.54 million yuan, reflecting a year-on-year increase of 7.64% [1]

Core Viewpoint - Reap Bio announced the convening of its 29th temporary board meeting on October 24, 2025, to review the proposal for the Q3 2025 report [1] Company Summary - For the year 2024, Reap Bio's revenue composition is as follows: 43.12% from veterinary biological products, 33.86% from veterinary drugs, 20.63% from pet supply chain, and 2.38% from other sources [1] - As of the report, Reap Bio's market capitalization stands at 9.7 billion yuan [1] Industry Summary - The Chinese innovative drug sector has seen significant overseas licensing sales, totaling 80 billion USD this year [1] - There is a contrast in the biopharmaceutical secondary market's activity compared to the primary market, where fundraising has encountered challenges [1]

Core Viewpoint - Reap Bio (300119) reported its Q3 2025 results, showing modest revenue growth and significant profit increase compared to the previous year [1] Financial Performance - In Q3 2025, the company achieved revenue of 837 million, representing a year-on-year growth of 1.44% [1] - The net profit attributable to shareholders for Q3 2025 was 106 million, reflecting a year-on-year increase of 23.02% [1] - For the first three quarters of 2025, the total revenue reached 2.544 billion, with a year-on-year growth of 13.5% [1] - The net profit attributable to shareholders for the first three quarters was 362 million, marking a year-on-year increase of 45.64% [1]

证券代码：300119 证券简称：瑞普生物 公告编号：2025-087 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 瑞普生物股份有限公司《2025年第三季度报告》已于2025年10月25日在深圳 证券交易所网站（http://www.szse.cn）及巨潮资讯网（http://www.cninfo.com.cn） 披露，请投资者注意查阅！ 特此公告。 瑞普生物股份有限公司董事会 二〇二五年十月二十五日 1 瑞普生物股份有限公司 2025年第三季度报告披露提示性公告 ...

证券代码：300119 证券简称：瑞普生物 公告编号：2025-088 瑞普生物股份有限公司 关于设立及变更募集资金专户并授权签署三方监管协议的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 瑞普生物股份有限公司（以下简称"公司""瑞普生物"）于 2025 年 10 月 24 日召开第五届董事会第二十九次（临时）会议及第五届监事会第二十五次 （临时）会议，审议通过了《关于设立及变更募集资金专户并授权签署三方监管 协议的议案》，同意根据 2021 年向特定对象发行股票部分募集资金投资项目变 更需求，在渤海银行开立新的募集资金专项账户，并变更原在平安银行（账号： 15535008370073）、中国建设银行（账号：12050162660100002432）开立的募集 资金专户用途为"生物制造产业化工程建设项目"。董事会授权董事长及董事长 授权的人员办理开立及变更募集资金专项账户相关事宜，包括但不限于开立募集 资金专项账户、签署募集资金专户存储三方监管协议等。 现将具体情况公告如下： 一、募集资金基本情况 经中国证券监督管理委员会于 2021 年 9 月 10 ...

证券代码：300119 证券简称：瑞普生物 公告编号：2025-085 瑞普生物股份有限公司 表决结果：同意 3 票，反对 0 票，弃权 0 票。 2、审议通过了《关于设立及变更募集资金专户并授权签署三方监管协议的 议案》 第五届监事会第二十五次（临时）会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 一、监事会会议召开情况 瑞普生物股份有限公司（以下简称"公司"）第五届监事会第二十五次（临 时）会议于 2025 年 10 月 24 日在公司会议室以现场表决方式召开。会议通知于 2025 年 10 月 21 日以书面及电子邮件等方式送达全体监事。公司应出席监事 3 人，实际出席监事 3 人，参与表决监事 3 人。本次会议由监事会主席周仲华先生 主持。本次会议的召集、召开和表决程序符合《公司法》《证券法》等法律法规 和《公司章程》的规定。 二、监事会会议审议情况 1、审议通过了《关于 2025 年第三季度报告的议案》 经审议，监事会认为公司《2025 年第三季度报告》编制及审议程序符合法 律、行政法规和中国证监会等相关规定，报告内容真实、准确、完整地 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 一、董事会会议召开情况 瑞普生物股份有限公司（以下简称"公司"）第五届董事会第二十九次（临 时）会议于 2025 年 10 月 24 日在公司会议室以现场结合通讯表决方式召开。会 议通知于 2025 年 10 月 21 日以书面及电子邮件等方式送达全体董事。公司应出 席董事 9 人，实际出席董事 9 人（其中：董事刘爱玲、李睿、杨鶄，独立董事郭 春林、才学鹏、李娅以通讯方式参会），参与表决董事 9 人。本次会议由董事长 李守军先生主持，公司高级管理人员列席了会议。本次会议的召集、召开和表决 程序符合《公司法》《证券法》等法律法规和《公司章程》的规定。 二、董事会会议审议情况 1、审议通过了《关于 2025 年第三季度报告的议案》 经审议，董事会认为《2025 年第三季度报告》编制和审核的程序符合法律、 行政法规和中国证监会等相关规定，报告内容真实、准确、完整地反映了公司 2025 年三季度的经营状况，不存在任何虚假记载、误导性陈述或者重大遗漏。 公司董事、监事、高级管理人员对该报告签署了书面确认意见。 具体内容详 ...

Financial Performance - The company's revenue for Q3 2025 reached ¥836,737,374.53, representing a year-on-year increase of 1.44%[5] - Net profit attributable to shareholders for Q3 2025 was ¥105,784,584.02, up 23.02% compared to the same period last year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥81,536,762.58, reflecting a 7.64% increase year-on-year[5] - For the first nine months of 2025, the company achieved a total revenue of ¥2,544,325,031.33, a 13.50% increase from the previous year[9] - The net profit attributable to shareholders for the first nine months was ¥362,307,052.90, which is a 45.64% increase year-on-year[9] - Operating profit for the current period was ¥442,271,734.21, up 39.6% from ¥316,434,076.01 in the previous period[27] - Net profit attributable to shareholders of the parent company was ¥362,307,052.90, representing a 45.6% increase from ¥248,766,437.96 in the previous period[28] - Earnings per share (EPS) for the current period was ¥0.7972, up from ¥0.5401 in the previous period[28] Cash Flow and Assets - The company's cash flow from operating activities for the first nine months was ¥205,880,305.22, down 45.46% compared to the previous year[11] - The company's short-term borrowings decreased to 736.81 million yuan from 800.78 million yuan[25] - Accounts payable decreased to 320.68 million yuan from 362.87 million yuan[25] - The company reported a net cash flow from operating activities of ¥205,880,305.22, down 45.4% from ¥377,458,172.51 in the previous period[30] - The company generated cash inflows from investment activities totaling ¥2,254,967,689.98, a decrease from ¥2,604,449,087.07 in the previous period[30] - Cash and cash equivalents at the end of the period increased to $486.83 million, up from $350.51 million, representing a growth of approximately 39%[31] - The company’s cash flow from investment activities showed a net inflow of $60.29 million, a turnaround from a net outflow of -$269.18 million previously[31] Assets and Liabilities - The total assets at the end of Q3 2025 were ¥7,690,888,248.95, a decrease of 3.45% from the end of the previous year[5] - Total liabilities decreased to ¥2,540,845,487.30 from ¥2,958,832,996.02, a reduction of 14.1%[26] - Total equity increased to ¥5,150,042,761.65 from ¥5,006,960,057.85, reflecting a growth of 2.8%[26] - Current assets totaled 3.61 billion yuan, a decrease from 3.65 billion yuan at the start of the period[24] - The company's non-current assets totaled 4.08 billion yuan, down from 4.32 billion yuan at the beginning of the period[25] Shareholder Information - The total number of common shareholders at the end of the reporting period is 25,144[13] - The largest shareholder, Li Shoujun, holds 36.04% of shares, totaling 167,474,479 shares, with 125,605,859 shares pledged[13] - The second-largest shareholder, Liang Wu, holds 5.04% of shares, totaling 23,405,578 shares, with 11,730,000 shares pledged[13] - The total number of restricted shares at the beginning of the period was 130,866,730, with 1,093,425 shares released and 19,380 shares added, resulting in 129,792,685 restricted shares at the end of the period[17] - The company has a high concentration of ownership, with the top five shareholders holding over 50% of the total shares[13] - The company has not reported any changes in the number of preferred shareholders or their holdings[15] Research and Development - Research and development expenses rose to ¥157,025,388.67, an increase of 16.2% compared to ¥135,162,744.28 in the previous period[27] - The company received clinical trial approval for the world's first mRNA vaccine for food animals, enhancing its product line and industry reputation[18] - In Q3, the company obtained approvals for 7 new veterinary products, including vaccines and antibiotics, to strengthen its product matrix in the pet and livestock medicine sectors[18] Investments and Projects - The company has changed part of its fundraising purpose to invest 296 million yuan in a microbial protein industrialization project, with a total investment of 679 million yuan[20] - A joint venture was established with Shengwei Biotechnology to develop vaccines for ruminants, with the company investing 27 million yuan for a 43.55% stake[22] Other Financial Information - The company completed the cancellation of 1,093,200 restricted stock units, reducing its registered capital from 465,847,906 yuan to 464,754,706 yuan[21] - The impact of exchange rate changes on cash and cash equivalents was a positive $196,030.85, down from $392,159.94, reflecting a decrease of approximately 50%[31] - The third quarter financial report was not audited, which may affect the reliability of the reported figures[32]